ars pharmaceuticals inc - SPRY
SPRY
Close Chg Chg %
10.03 -0.07 -0.70%
Closed Market
9.96
-0.07 (0.70%)
Volume: 2.80M
Last Updated:
Sep 15, 2025, 4:00 PM EDT
Company Overview: ars pharmaceuticals inc - SPRY
SPRY Key Data
| Open $10.07 | Day Range 9.78 - 10.11 |
| 52 Week Range 9.78 - 18.89 | Market Cap $991.23M |
| Shares Outstanding 98.83M | Public Float 58.37M |
| Beta 0.87 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.49 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.11M |
SPRY Performance
| 1 Week | 0.00% | ||
| 1 Month | -30.97% | ||
| 3 Months | -34.83% | ||
| 1 Year | -24.59% | ||
| 5 Years | N/A |
SPRY Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About ars pharmaceuticals inc - SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
SPRY At a Glance
ARS Pharmaceuticals, Inc.
11682 El Camino Real
San Diego, California 92130
| Phone | 1-858-771-9307 | Revenue | 89.15M | |
| Industry | Pharmaceuticals: Major | Net Income | 8.00M | |
| Sector | Health Technology | 2024 Sales Growth | 297,063.333% | |
| Fiscal Year-end | 12 / 2025 | Employees | 160 | |
| View SEC Filings |
SPRY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 135.083 |
| Price to Sales Ratio | 12.117 |
| Price to Book Ratio | 4.024 |
| Price to Cash Flow Ratio | 79.73 |
| Enterprise Value to EBITDA | -266.519 |
| Enterprise Value to Sales | 8.595 |
| Total Debt to Enterprise Value | 0.00 |
SPRY Efficiency
| Revenue/Employee | 557,181.25 |
| Income Per Employee | 49,987.50 |
| Receivables Turnover | 9.73 |
| Total Asset Turnover | 0.305 |
SPRY Liquidity
| Current Ratio | 14.262 |
| Quick Ratio | 14.039 |
| Cash Ratio | 13.397 |
SPRY Profitability
| Gross Margin | 98.671 |
| Operating Margin | -3.458 |
| Pretax Margin | 9.295 |
| Net Margin | 8.971 |
| Return on Assets | 2.737 |
| Return on Equity | 3.281 |
| Return on Total Capital | 3.114 |
| Return on Invested Capital | 3.281 |
SPRY Capital Structure
| Total Debt to Total Equity | 0.016 |
| Total Debt to Total Capital | 0.016 |
| Total Debt to Total Assets | 0.012 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ars Pharmaceuticals Inc - SPRY
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 1.32M | 30.00K | 89.15M | |
Sales Growth
| - | - | -97.72% | +297,063.33% | - |
Cost of Goods Sold (COGS) incl D&A
| 1.93M | 319.00K | 73.00K | 1.19M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.93M | 319.00K | 73.00K | 208.00K | |
Depreciation
| 1.93M | 319.00K | 73.00K | 79.00K | |
Amortization of Intangibles
| - | - | - | 129.00K | - |
COGS Growth
| +12.81% | -83.46% | -77.12% | +1,523.29% | |
Gross Income
| (1.93M) | 997.00K | (43.00K) | 87.96M | |
Gross Income Growth
| -12.81% | +151.68% | -104.31% | +204,667.44% | |
Gross Profit Margin
| - | +75.76% | -143.33% | +98.67% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 87.66M | 36.51M | 67.48M | 91.05M | |
Research & Development
| 60.72M | 18.38M | 20.27M | 19.58M | |
Other SG&A
| 26.94M | 18.14M | 47.21M | 71.47M | |
SGA Growth
| +180.87% | -58.34% | +84.80% | +34.93% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 140.00K | - |
EBIT after Unusual Expense
| (89.58M) | (35.66M) | (67.52M) | (3.08M) | |
Non Operating Income/Expense
| 106.00K | 974.00K | 13.15M | 11.37M | |
Non-Operating Interest Income
| - | - | - | 106.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (89.48M) | (34.68M) | (54.37M) | 8.29M | |
Pretax Income Growth
| -171.58% | +61.24% | -56.75% | +115.24% | |
Pretax Margin
| - | -2,635.41% | -181,216.67% | +9.29% | |
Income Tax
| - | - | - | 288.00K | - |
Income Tax - Current - Domestic
| - | - | - | 288.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (89.48M) | (34.68M) | (54.37M) | 8.00M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (89.48M) | (34.68M) | (54.37M) | 8.00M | |
Net Income Growth
| -171.58% | +61.24% | -56.75% | +114.71% | |
Net Margin Growth
| - | -2,635.41% | -181,216.67% | +8.97% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (89.48M) | (34.68M) | (54.37M) | 8.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (89.48M) | (34.68M) | (54.37M) | 8.00M | |
EPS (Basic)
| -2.5619 | -0.868 | -0.571 | 0.0825 | |
EPS (Basic) Growth
| -169.84% | +66.12% | +34.22% | +114.45% | |
Basic Shares Outstanding
| 34.93M | 39.96M | 95.22M | 96.94M | |
EPS (Diluted)
| -2.5619 | -0.868 | -0.571 | 0.0781 | |
EPS (Diluted) Growth
| -169.84% | +66.12% | +34.22% | +113.68% | |
Diluted Shares Outstanding
| 34.93M | 39.96M | 95.22M | 102.39M | |
EBITDA
| (87.66M) | (35.20M) | (67.45M) | (2.88M) | |
EBITDA Growth
| -180.87% | +59.85% | -91.63% | +95.74% | |
EBITDA Margin
| - | -2,674.54% | -224,823.33% | -3.22% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 31.00 | |
| Number of Ratings | 7 | Current Quarters Estimate | -0.458 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | -1.598 | |
| Last Quarter’s Earnings | -0.46 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.08 | Next Fiscal Year Estimate | -0.806 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 7 | 7 |
| Mean Estimate | -0.46 | -0.32 | -1.60 | -0.81 |
| High Estimates | -0.39 | -0.13 | -1.39 | -0.17 |
| Low Estimate | -0.56 | -0.55 | -1.92 | -1.28 |
| Coefficient of Variance | -12.00 | -41.18 | -10.84 | -45.59 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 6 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Ars Pharmaceuticals Inc - SPRY
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ars Pharmaceuticals Inc - SPRY
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 9, 2025 | Laura K. Shawver Director | 232,855 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.85 per share | 1,129,346.75 |
| Apr 9, 2025 | Laura K. Shawver Director | 260,348 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.85 per share | 1,262,687.80 |
| Apr 9, 2025 | Laura K. Shawver Director | 210,346 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.3 per share | 2,587,255.80 |
| Apr 9, 2025 | Laura K. Shawver Director | 51,555 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 9, 2025 | Laura K. Shawver Director | 24,062 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2025 | Eric Karas Chief Commercial Officer | 17,696 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.5 per share | 26,544.00 |
| Mar 24, 2025 | Eric Karas Chief Commercial Officer | 7,696 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14 per share | 107,744.00 |
| Mar 24, 2025 | Eric Karas Chief Commercial Officer | 574,588 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Brian T. Dorsey Chief Operating Officer | 261,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Kathleen D. Scott Chief Financial Officer | 176,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Alexander A. Fitzpatrick Chief Legal Officer | 152,300 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Richard E. Lowenthal PRESIDENT AND CEO; Director | 767,600 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Richard E. Lowenthal PRESIDENT AND CEO; Director | 261,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Justin Chakma Chief Business Officer | 274,100 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Sarina Tanimoto CHIEF MEDICAL OFFICER | 261,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Sarina Tanimoto CHIEF MEDICAL OFFICER | 767,600 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |